Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core

加速药物合作——自身免疫和免疫疾病组织研究核心

• 批准号: 10596177
• 负责人: Joel Marvin Guthridge
• 金额: $ 728.96万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-23 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10596177
• 关键词: Acceleration; Attention; Autoimmune; Autoimmune Diseases; Awareness; Biological Markers; Biopsy; Biotechnology; Caring; Cells; Certification; Characteristics; Cladribine; Clinical; Collection; Country; Data; Data Protection; Data Set; Database Management Systems; Dedications; Disease; Emerging Technologies; Ensure; Equipment and supply inventories; Foundations; Genetic; Histology; Image; Immune; Immune System Diseases; Industry Standard; Information Systems; Infrastructure; Institution; Institutional Review Boards; International; Investments; Knowledge; Leadership; Location; Logistics; Lupus; Lupus Erythematosus; Manuals; Measurement; Mediating; Medical Research; Medicine; Methods; Mission; Modality; Molecular; Molecular Profiling; Monitor; Multiomic Data; Oklahoma; Pathology; Patients; Phenotype; Play; Positioning Attribute; Procedures; Process; Protocols documentation; Psoriasis; Quality Control; Recording of previous events; Research; Rheumatoid Arthritis; Sampling; Science; Secure; Services; Shipping; Site; Sjogren' s Syndrome; Solid; Space Perception; Staff Development; Standardization; Support System; System; Systemic Lupus Erythematosus; Technology; Testing; Tissue Banks; Tissue Sample; Tissue imaging; Tissues; Training; Universities; Work; adjudication; biobank; clinical application; clinically actionable; cohort; cost effective; design; digital imaging; digital pathology; distributed data; experience; high dimensionality; improved; innovation; interest; migration; multiple omics; phenotypic biomarker; programs; repository; single cell analysis; social; success; transcriptomics

Project Summary The successful Accelerating Medicines Partnership in RA/Lupus (AMP1) program focused on deconstructing disease tissues through single-cell transcriptomic technologies. AMP in Autoimmune and Immune-Mediated Diseases (AMP AIM) is poised to expand the understanding of the cellular components and interactions at play in four autoimmune disease target tissues with new spatially-oriented modalities of single-cell analyses. As in the AMP1, the AMP AIM will require high-quality samples for interrogation, standardized methods to assess sample quality and common molecular/phenotypic biomarker testing across all subjects for a clinically and molecularly well-phenotyped cohort to apply new cutting-edge technologies to re-construct disease. The OMRF tissue research core (TRC) is uniquely positioned to successfully deploy a centralized TRC across all Disease Teams for Lupus (SLE), RA, Sjogren’s Disease (SjD), and Psoriatic Spectrum Diseases (PSD). With a robust, existing infrastructure, capabilities, and leadership, the OMRF TRC will provide the Network with: 1) standardized protocols and manuals to be used across all parts of the Network, 2) centralized logistics for collection, transport, storage and dissemination, 3) centralized, trans-disease QC and initial testing of all samples in a continuous manner as samples are collected for early quality management and identification of samples of high importance, 4) tissue imaging (basic histology & initial high-dimensional) utilizing sample sparing workflows that provide scoring and QC of tissue, plus initial multi-omic, spatially-informed data sets, and 5) industry standard repository and image database systems. The OMRF TRC is centrally located, making it an ideal location for logistics management and, since it was the repository for AMP1 carries Network knowledge along with the extensive experience as repository for multiple other national consortiums, provides for continuity during transition to AMP AIM. The OMRF TRC already has infrastructure in place and the reputation that follows from strong leadership to continue to act as an ideal honest broker for the Network. The OMRF TRC has state-of-the-art facilities that are integrated with advanced technologies within its associated cores to receive, store, collect meaningful QC and initial data sets, and disseminate selected samples to technology and analytic cores (TAC) poised to provide data from emerging technologies to build upon the deep clinical and initial characterization data, to make extremely high- dimensional, robust datasets. Considering the longstanding history of the OMRF TRC in biobanking samples for autoimmune disease studies, the OMRF TRC is poised to a produce a solid foundation of banked samples, organized logistics, and initial multi-omic datasets that will setup the Network for success in reconstructing our mechanistic understanding and clinical application of these new data to better treat these autoimmune diseases.

项目概要 成功的加速 RA/狼疮药物合作伙伴关系 (AMP1) 计划的重点是解构 通过单细胞转录组技术研究疾病组织。自身免疫和免疫介导中的 AMP 疾病 (AMP AIM) 有望扩大对细胞成分和相互作用的理解 在四种自身免疫性疾病的靶组织中，采用新的单细胞分析空间定向模式。如在 AMP1、AMP AIM 将需要高质量的样本进行询问、标准化的方法来评估 所有受试者的样本质量和常见分子/表型生物标志物测试，以进行临床和 分子表型良好的队列应用新的尖端技术来重建疾病。 OMRF 组织研究核心 (TRC) 具有独特的优势，可以成功部署集中式 TRC 涵盖狼疮 (SLE)、RA、干燥病 (SjD) 和银屑病谱系疾病的所有疾病团队 （PSD）。凭借强大的现有基础设施、能力和领导力，OMRF TRC 将提供 网络具有：1）在网络所有部分使用的标准化协议和手册，2）集中式 收集、运输、储存和传播的物流，3) 集中、跨疾病的质量控制和初步测试 收集样品以进行早期质量管理和识别时，以连续方式收集所有样品 高度重要的样本，4) 利用样本进行组织成像（基本组织学和初始高维） 节省提供组织评分和质量控制的工作流程，以及初始多组学、空间信息数据集， 5) 行业标准存储库和图像数据库系统。 OMRF TRC 位于中心位置，使其成为物流管理的理想地点，并且由于它是 AMP1 的存储库承载了网络知识以及作为存储库的丰富经验 多个其他国家联盟，在向 AMP AIM 过渡期间提供连续性。 OMRF TRC 已经拥有适当的基础设施和强大的领导力所带来的声誉，可以继续充当 网络理想的诚实经纪人。 OMRF TRC 拥有最先进的设施，与 其相关核心内的先进技术用于接收、存储、收集有意义的质量控制和初始数据集， 并将选定的样本分发给准备提供数据的技术和分析核心（TAC） 新兴技术以深入的临床和初始表征数据为基础，使极高的 多维、稳健的数据集。 考虑到 OMRF TRC 在自身免疫性疾病生物样本库样本中的悠久历史 研究表明，OMRF TRC 准备为银行样本、有组织的物流和 初始多组学数据集将设置网络以成功重建我们的机制 了解和临床应用这些新数据可以更好地治疗这些自身免疫性疾病。